High Tide Therapeutics
Pharmaceuticals, Rockville Pike Ste 100-551, Shenzhen, , 20852, Maryland, 11140, United States, 51-200 Employees
Who is HIGHTIDE THERAPEUTICS
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications ...
Read More
-
Headquarters: 11140 Rockville Pike Ste 100-551, Shenzhen, Maryland, 20852, United States
-
Date Founded: 2011
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
Does something look wrong? Fix it. | View contact records from HIGHTIDE THERAPEUTICS
HighTide Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to HighTide Therapeutics
Akero Therapeutics
-
11-50
-
$ 1 Million to 5 Million
Arcus Biosciences
-
501-1000
-
$ 250 Million to 500 Million
Crinetics Pharmaceuticals
-
201-500
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding HighTide Therapeutics
Answer: HighTide Therapeutics's headquarters are located at Rockville Pike Ste 100-551, Shenzhen, , 20852, Maryland, 11140, United States
Answer: HighTide Therapeutics's official website is https://hightidetx.com
Answer: HighTide Therapeutics's revenue is $10 Million to $25 Million
Answer: HighTide Therapeutics has 51-200 employees
Answer: HighTide Therapeutics is in Pharmaceuticals
Answer: HighTide Therapeutics top competitors include: Akero Therapeutics , Arcus Biosciences , Crinetics Pharmaceuticals
Answer: HighTide Therapeutics contact info: Phone number: Website: https://hightidetx.com
Answer: HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the companys lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month